Please ensure Javascript is enabled for purposes of website accessibility

3 Things to Watch With Pfizer's Zoetis IPO

By Keith Speights – Updated Apr 7, 2017 at 1:05PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Watch for these factors with Pfizer's animal health business spin-off plans.

Pfizer (NYSE: PFE) announced in June that it planned to spin off its animal health business via an IPO. The company moved the ball forward in mid-August by registering the IPO with regulators. The IPO for the new company, Zoetis, is planned for the first half of 2013.

That day will come quickly, so it's never too early to consider the impact for Pfizer -- and Zoetis --shareholders. Here are three things for investors to watch.

1. Which end of the leash do you want?
Pfizer's IPO registration indicated that the company will sell up to 20% of Zoetis. That means that Pfizer seems likely to hold Zoetis on a pretty tight leash, at least at the start.

There could be an interesting decision for current Pfizer shareholders to make. The company may allow investors to swap a portion of their Pfizer shares for Zoetis shares. A decision on this hasn't been finalized, but it raises the question of which company would be the better pick.

A good case can be made for Zoetis over Pfizer. New animal pharmaceuticals can typically be brought to market more quickly and less expensively than those for humans. Concerns about how much government programs or insurance companies will reimburse are minimal. And Zoetis won't have the loss of patent exclusivity on its best-selling drug to worry about.

Current Pfizer shareholders should keep a close watch on their alternatives with the Zoetis IPO. The potential to swap out shares might be one to seriously consider.

2. How wild will the call of the wild be?
Merely mentioning the term "IPO" brings the animal out in some investors. Their hair grows longer, and their teeth become sharper. They can't wait to pounce on that red meat Wall Street refers to as an IPO. To some, IPOs are tantamount to a call of the wild.

The Zoetis IPO should attract plenty of investor interest. Pfizer's animal health unit is solid, with 2011 revenue of $4.2 billion. That amount increased by 17% compared with the prior year.

Prospective Zoetis investors should look out, though, for the pricing on the new company's shares. Several analysts value the business around $15 billion. Watch the IPO share price to make sure that it doesn't peg a ridiculously higher valuation to the new company. Sometimes, the call of the wild can be too wild.

3. Grazing in new pastures?
Pfizer currently claims a 19% share of the animal pharmaceuticals market. That ranks the company as the largest in the field.

Other big pharmaceutical companies also compete in the animal health market. The animal health business segment of Merck (NYSE: MRK) brought in more than $3.2 billion in 2011. Merial, a division of Sanofi (NYSE: SNY), garnered well over $2 billion in sales.

What could be interesting to see is if Zoetis expands its business to compete more heavily in animal diagnostics. While Pfizer maintains a presence in animal diagnostics, IDEXX Laboratories (Nasdaq: IDXX) stands atop the niche market with $1.2 billion in sales. Abaxis (Nasdaq: ABAX) trails behind with around $156 million in sales.

It remains to be seen if the sole focus on animal health will result in Zoetis grazing in new pastures or perhaps gobbling up a smaller player. Watch for any signs that the new company plans to follow this path of expansion. Such a move could mean faster growth.

Wait, watch and win
Zoetis seems positioned to be a good choice for investors when it goes public in 2013. The animal health business has proven to be a profitable one for Pfizer through the years.

Investors should win through this spin-off. Pfizer gets to raise more cash to help with its dilemma of funding R&D to replace cash-cow drugs losing patent protection as the revenue from those drugs drops off. That could improve the prospects for its stock.

Current Pfizer shareholders also will gain ownership in a promising new public entity. With any luck, they will even have the alternative of trading Pfizer shares for Zoetis shares. We don't know yet if that would be the best thing to do, but having options is always nice. For now, investors can wait, watch, and prepare to win.

If you like hunting for potential big winners like the Zoetis IPO, check out the Fool's new free report titled "Middle-Class Millionaire-Makers: 3 Stocks Wall Street's Too Rich to Notice." Get your free copy now!

Fool contributor Keith Speights owns no shares in the stocks mentioned above. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$43.76 (-0.91%) $0.40
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$86.12 (-0.60%) $0.52
Sanofi Stock Quote
$38.02 (0.05%) $0.02
Abaxis, Inc. Stock Quote
Abaxis, Inc.
IDEXX Laboratories, Inc. Stock Quote
IDEXX Laboratories, Inc.
$325.80 (-1.81%) $-6.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.